ALT:NSD-Altimmune, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.35

Change

+1.44 (+11.15)%

Market Cap

USD 0.48B

Volume

2.32M

Average Target Price

USD 27.25 (+89.90%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Company Website : http://altimmune.com

Address : 910 Clopper Road, Gaithersburg, MD, United States, 20878

Employees : 25

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.42

52 Week High : 35.10

Short Ratio : 1.35

52 Week Low : 1.60

Shorted Shares : 2,926,944

200 Day Moving Average : 15.73

Shorted Shares Previous Month : 2,487,463

50 Day Moving Average : 12.74

Shares Held By Insiders : 65.14%

Short Percentage : 8.00%

Shares Held by Institutions : 67.3%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.05 (-0.44%)

 USD62.06B 23.39 18.26
REGN Regeneron Pharmaceuticals, Inc

+2.30 (+0.43%)

 USD57.14B 19.62 14.64
MRNA Moderna, Inc

-1.96 (-1.47%)

 USD52.62B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.87 (+1.18%)

 USD34.53B 36.64 33.83
SGEN Seagen Inc

-3.03 (-1.63%)

 USD33.25B 70.16 70.76
BGNE BeiGene, Ltd

+17.51 (+4.90%)

 USD32.53B N/A N/A
RPRX Royalty Pharma plc

+0.74 (+1.47%)

 USD31.52B 22.60 11.90
GMAB Genmab A/S

-0.01 (-0.02%)

 USD28.49B 26.59 3.08
BNTX BioNTech SE

+3.01 (+2.85%)

 USD25.39B -99,999.99 N/A
INCY Incyte Corporation

+3.99 (+4.25%)

 USD20.56B 47.64 35.20

ETFs Containing ALT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.22% 71% C- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.22% 71% C- 85% B
Trailing 12 Months  
Capital Gain 651.31% 98% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 651.31% 98% A+ 97% A+
Trailing 5 Years  
Capital Gain -72.19% 23% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.19% 23% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain 63.53% 83% B 92% A-
Dividend Return 40.30% 90% A- 100% A+
Total Return 103.83% 91% A- 96% A
Risk Return Profile  
Volatility (Standard Deviation) 257.67% 8% F 4% F
Risk Adjusted Return 40.29% 68% D+ 64% D
Market Capitalization 0.48B 57% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.82 71% C- 90% A-
Price/Book Ratio 2.40 78% C+ 55% F
Price / Cash Flow Ratio -49.94 89% B+ 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -34.14% 75% C 28% F
Return on Invested Capital -43.86% 68% D+ 21% F
Return on Assets -10.96% 85% B 27% F
Debt to Equity Ratio 4.10% 75% C 84% B
Technical Ratios  
Short Ratio 1.35 67% D+ 67% D+
Short Percent 9.07% 36% F 24% F
Beta 1.42 54% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector